Boston- Please join us on Wednesday, July 18th, 2018 for an evening of sharing, learning, and socializing with fellow Boston QSP community members at the Boston QSP July Event "Quantitative & Systems Pharmacology (QSP) in Drug Discovery."
The event will feature a presentation titled "Putting the Drug in Drug Development with Quantitative Translational Pharmacology" by our distinguished speaker Dr. Tristan Maurer. The event will be chaired by Dr. Gianluca Nucci, Vice President, Early Clinical Development, Head of Clinical Pharmacology at Pfizer. Dr. Nucci is also one of our Scientific Advisors at Boston QSP. It will be followed by a mixer and reception where you can enjoy great company and conversation with fellow community members over selected craft beers and food from a local small business.
Registration is free but RSVP is required. The event is sponsored by Pfizer.
5:30-6:20 PM: Presentation and Q&A. Presentation title: Putting the Drug in Drug Development with Quantitative Translational Pharmacology (Havana Room)
6:20-7:30 PM: Mixer & Reception (Venture Café, a few steps down the hallway from the Havana room)
Venue: Cambridge Innovation Center, 1 Broadway, Cambridge.
RSVP here. Limited seats.
* Please do not hesitate to RSVP on the waiting list if the RSVP is full as some guests "un-RSVP" as the event gets closer.
Dr. Maurer is the Senior Director of Translational Modeling & Simulation at Pfizer, Department of Medicine Design, based in Cambridge MA. After obtaining his PharmD from University of Georgia and his Ph.D. from University at Buffalo, State University of New York, Dr. Maurer joined Pfizer in 1999. During his 19-year tenure with Pfizer, his work has focused on the development and application of biologically-relevant mathematical models to predict the pharmacokinetics & pharmacodynamics of novel therapeutic agents in humans. In addition, Dr. Maurer has served as a graduate student and postdoc mentor and collaborator with leading universities in the field of Pharmacokinetics and Pharmacodynamics, including University at Buffalo, University of Manchester, The University of North Carolina at Chapel Hill, and UC San Francisco. Currently, he leads a preclinical translational pharmacology group responsible for both cheminformatic and biologically-based M&S across Pfizer's entire small molecule portfolio.
In drug development, the intrinsic potential of a molecule to become a drug is sealed by the end of the lead optimization stage. At the enterprise level, this is the most expensive stage of the R&D process due (in large part) to the high rates of attrition in the latter stages of drug development. As such, optimization of this and prior stages of R&D is essential in order to address the productivity challenges facing the industry and to ensure that we continue to have the opportunity to deliver impactful medicines to patients. While quantitative pharmacology approaches have significant potential to address this challenge, a greater focus on their application in the early preclinical stages is essential. This talk will cover ongoing efforts to systematically leverage a variety of quantitative translational pharmacology approaches in the early preclinical stages of R&D for the sake of putting drugs into the later, clinical stages of drug development. A special emphasis will be placed on applications in lead optimization which ultimately seek to bridge desired clinical outcomes, laboratory objectives and chemical structure in a way that enables drug design.
About Boston QSP
Boston QSP is a 501(c)(3) non-profit organization whose mission is to foster the sharing of QSP knowledge, challenges, solutions, and opportunities to advance the field as an interdisciplinary community in Boston.